Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia

The negative regulator of p53, MDM2, is frequently overexpressed in acute myeloid leukemia (AML) that retains wild-type TP53 alleles. Targeting of p53-MDM2 interaction to reactivate p53 function is therefore an attractive therapeutic approach for AML. Here we show that an orally active inhibitor of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Yasutaka, Goyama, Susumu, Liu, XiaoXiao, Tamura, Moe, Asada, Shuhei, Tanaka, Yosuke, Fukuyama, Tomofusa, Wunderlich, Mark, O’Brien, Eric, Mizukawa, Benjamin, Yamazaki, Satoshi, Matsumoto, Akiko, Yamasaki, Satoshi, Shibata, Tatsuhiro, Matsuda, Koichi, Sashida, Goro, Takizawa, Hitoshi, Kitamura, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814808/
https://www.ncbi.nlm.nih.gov/pubmed/31653912
http://dx.doi.org/10.1038/s41467-019-12555-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814808/
https://www.ncbi.nlm.nih.gov/pubmed/31653912
http://dx.doi.org/10.1038/s41467-019-12555-1

Ejemplares similares